AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8874912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.2 mg.kg‐1 i.m.
Number of subjects: 148
Study 8874912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.06 mg.kg‐1 i.v.
Number of subjects: 148
Study 8874912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.1 mg.kg‐1 i.v.
Number of subjects: 148
Study 8874912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) 0.02 ml.kg‐1 i.v.
Number of subjects: 148
Study 1574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) 300 U/kg subcutaneously 3 times weekly for 6 months
Number of subjects: 30
Study 1574960 — intervention group
Group type: COMPARATOR
Intervention: Conventional support alone (control)
Number of subjects: 30
Study 3881068 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial impedance plethysmography alone
Number of subjects: 634
Study 3881068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined impedance plethysmography and leg scanning
Number of subjects: 634
Study 29209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) assessment
Number of subjects: 81
Study 29209951 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline late heart-to-mediastinum ratio (HMR)
Number of subjects: 81
Study 29209951 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS assessment at baseline
Number of subjects: 81
Study 29209951 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS cut-off of -9%
Number of subjects: 81
Study 29801081 — intervention group
Group type: EXPERIMENTAL
Intervention: Early referral to the vision center for refraction and free eyeglasses if needed (n=433)
Number of subjects: 2613
Study 29801081 — intervention group
Group type: COMPARATOR
Intervention: Late referral to the vision center for refraction and free eyeglasses if needed (n=516)
Number of subjects: 2613
Study 26739975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μ/kg dexmedetomidine
Number of subjects: 75
Study 26739975 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μ/kg intravenous ketamine
Number of subjects: 75
Study 26739975 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 75
Study 24966055 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care
Number of subjects: 783
Study 24966055 — intervention group
Group type: COMPARATOR
Intervention: Protocolized care
Number of subjects: 783
Study 24966055 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 783
Study 22507606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based formula
Number of subjects: 58
Study 22507606 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed protein formula
Number of subjects: 58
Study 20805017 — intervention group
Group type: EXPERIMENTAL
Intervention: Allowed to drink at home with friends
Number of subjects: 449
Study 20805017 — intervention group
Group type: EXPERIMENTAL
Intervention: Allowed to drink at home with family meals
Number of subjects: 449
Study 20805017 — intervention group
Group type: COMPARATOR
Intervention: Not permitted to drink at all
Number of subjects: 449
Study 17909934 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteriorly stabilized total knee arthroplasty (PS TKA)
Number of subjects: 16
Study 16269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (215 microg/kg)
Number of subjects: 8
Study 16269092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (50 mg)
Number of subjects: 8
Study 16269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin and Ketanserin
Number of subjects: 8
Study 16269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 8
Study 16269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 8
Study 12175997 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturday night social activities (discotheque)
Number of subjects: 59
Study 12175997 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 59
Study 12175997 — intervention group
Group type: COMPARATOR
Intervention: Daytime assessment (9:00‐11:00 a.m.)
Number of subjects: 59
Study 10661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Harassment condition (telling stories with harassment)
Number of subjects: 102
Study 10661604 — intervention group
Group type: COMPARATOR
Intervention: Nonharassment condition (telling stories without harassment)
Number of subjects: 102
Study 8547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation Unit (GEU) care
Number of subjects: 249
Study 8547382 — intervention group
Group type: COMPARATOR
Intervention: Standard care in the National Health Care System (control group)
Number of subjects: 249
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous infusion
Number of subjects: 0
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral solution
Number of subjects: 0
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mg intravenous infusion
Number of subjects: 0
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg intravenous infusion
Number of subjects: 0
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 0
Study 2312764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration
Number of subjects: 0
Study 31359099 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review using STOPP/START criteria
Number of subjects: 180
Study 31359099 — intervention group
Group type: COMPARATOR
Intervention: Similar review without a recommendation
Number of subjects: 180
Study 28797048 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal condition (food placed near students)
Number of subjects: 41
Study 28797048 — intervention group
Group type: COMPARATOR
Intervention: Distal condition (food placed 6 meters away from students)
Number of subjects: 41
Study 28797048 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal condition
Number of subjects: 41
Study 28797048 — intervention group
Group type: COMPARATOR
Intervention: Distal condition
Number of subjects: 41
Study 28797048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 41
Study 25577461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection and quantitation of the α‐1 haptoglobin fragment in the culture medium.
Number of subjects: 53
Study 25577461 — intervention group
Group type: COMPARATOR
Intervention: Microscopic inspection of embryos during IVF process.
Number of subjects: 53
Study 23444965 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulin/no medication
Number of subjects: 40
Study 23444965 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulin/metformin
Number of subjects: 40
Study 23444965 — intervention group
Group type: COMPARATOR
Intervention: placebo/no medication
Number of subjects: 40
Study 23444965 — intervention group
Group type: COMPARATOR
Intervention: placebo/metformin
Number of subjects: 40
Study 21211642 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass AIT treatment (2,800 bioequivalent allergen units, approximately 15 μg of Phl p 5)
Number of subjects: 345
Study 19758607 — intervention group
Group type: COMPARATOR
Intervention: High doses of progestin and endometrial protective doses of estradiol, administered immediately after delivery and continuously during the first three months post-partum.
Number of subjects: 126
Study 19758607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 126
Study 18032935 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 240
Study 18032935 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 240
Study 15508056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levovist (1 g i.v. injection)
Number of subjects: 12
Study 11336120 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontist-delivered anti-tobacco counseling
Number of subjects: 154
Study 11336120 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning variables
Number of subjects: 154
Study 11336120 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives, tracking prescriptions, prompting positive feedback from patients, adopting anti-tobacco counseling models
Number of subjects: 154
Study 11336120 — intervention group
Group type: EXPERIMENTAL
Intervention: Training orthodontists
Number of subjects: 154
Study 11336120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing tobacco use
Number of subjects: 154
Study 9134645 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin generation markers (TAT and F1 + 2)
Number of subjects: 195
Study 9134645 — intervention group
Group type: EXPERIMENTAL
Intervention: F1 + 2
Number of subjects: 195
Study 9134645 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma cholesterol
Number of subjects: 195
Study 9134645 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin generation markers
Number of subjects: 195
Study 7928859 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink (CI) at 500 ml/h
Number of subjects: 14
Study 7928859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PI) at 500 ml/h
Number of subjects: 14
Study 2905341 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 69
Study 2905341 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 69
Study 2905341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/day
Number of subjects: 69
Study 2905341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg/day
Number of subjects: 69
Study 2905341 — intervention group
Group type: COMPARATOR
Intervention: All beta-blockers
Number of subjects: 69
Study 2905341 — intervention group
Group type: COMPARATOR
Intervention: None of the beta-blockers
Number of subjects: 69
Study 30586720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 110
Study 30586720 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 110
Study 28234152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic solution buffered to pH 6.1, three times daily before and during peak pollen season
Number of subjects: 40
Study 28234152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal treatment)
Number of subjects: 40
Study 26844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg/day)
Number of subjects: 54
Study 26844270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23965491 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin treatment group (172 patients)
Number of subjects: 341
Study 23965491 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (169 patients)
Number of subjects: 341
Study 21521833 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionalist-transfer strategy
Number of subjects: 334
Study 21521833 — intervention group
Group type: COMPARATOR
Intervention: Patient-transfer strategy
Number of subjects: 334
Study 18487568 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin 60 microg/kg once weekly for 10 doses
Number of subjects: 99
Study 18487568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 18487568 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin during hyperfractionated radiotherapy (n = 40)
Number of subjects: 99
Study 18487568 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin during standard radiation therapy (n = 59)
Number of subjects: 99
Study 18487568 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 99
Study 16947782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg as monotherapy
Number of subjects: 359
Study 16947782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg as monotherapy
Number of subjects: 359
Study 16947782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg plus MTX
Number of subjects: 359
Study 16947782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg plus MTX
Number of subjects: 359
Study 16947782 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 359
Study 16947782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 359
Study 12953124 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (Bu)
Number of subjects: 43
Study 12953124 — intervention group
Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 43
Study 10899092 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI pacemaker programmed to 80 bpm with hysteresis of 45 bpm (19 patients)
Number of subjects: 42
Study 10899092 — intervention group
Group type: COMPARATOR
Intervention: No pacemaker (23 patients)
Number of subjects: 42
Study 10899092 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI pacemaker
Number of subjects: 42
Study 10899092 — intervention group
Group type: COMPARATOR
Intervention: No pacemaker
Number of subjects: 42
Study 8810961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 372
Study 8810961 — intervention group
Group type: COMPARATOR
Intervention: Sequential compression device (SCD)
Number of subjects: 372
Study 8810961 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous impulse (AVI) compression system
Number of subjects: 372
Study 8810961 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 372
Study 8810961 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 372
Study 1349259 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (2 mg, single oral dose)
Number of subjects: 13
Study 1349259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 4047540 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g glucose screening test
Number of subjects: 230
Study 4047540 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g glucose polymer screening test
Number of subjects: 230
Study 4047540 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g glucose polymer tolerance test
Number of subjects: 230
Study 30945917 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 30945917 — intervention group
Group type: COMPARATOR
Intervention: Traditional vocational rehabilitation services
Number of subjects: 0
Study 28569097 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC Initial scales
Number of subjects: 0
Study 28569097 — intervention group
Group type: EXPERIMENTAL
Intervention: STIC total scales and subscales
Number of subjects: 0
Study 27101297 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT + RE
Number of subjects: 8
Study 27101297 — intervention group
Group type: COMPARATOR
Intervention: MICT + RE
Number of subjects: 8
Study 27101297 — intervention group
Group type: COMPARATOR
Intervention: RE
Number of subjects: 8
Study 26153084 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion therapy
Number of subjects: 478
Study 26153084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 rs2279343 wild-type AA genotype
Number of subjects: 478
Study 26153084 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6∗4 (rs2279343) variant
Number of subjects: 478
Study 26153084 — intervention group
Group type: COMPARATOR
Intervention: FTND and Issa scores
Number of subjects: 478
Study 24282511 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory clinics care
Number of subjects: 175
Study 21948034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Resurfacing (HR)
Number of subjects: 343
Study 21948034 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal-on-metal (MoM) total hip arthroplasty (THA)
Number of subjects: 343
Study 18469243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-zinc meals (4 mg Zn/d) with zinc tracer
Number of subjects: 9
Study 18469243 — intervention group
Group type: COMPARATOR
Intervention: Adequate-zinc meals (11 mg Zn/d) with zinc stable isotope tracer
Number of subjects: 9
Study 18469243 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate-zinc meals (11 mg Zn/d)
Number of subjects: 9
Study 18469243 — intervention group
Group type: COMPARATOR
Intervention: Low-zinc meals (4 mg Zn/d)
Number of subjects: 9
Study 16540792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated buffered pancreatic enzyme (EC buffered PE) containing 1.5 mEq of bicarbonate per capsule
Number of subjects: 21
Study 16540792 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteric-coated enzyme (EC-PE) capsule
Number of subjects: 21
Study 16540792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated buffered pancreatic enzyme (EC buffered PE)
Number of subjects: 21
Study 16540792 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteric-coated enzyme (EC-PE)
Number of subjects: 21
Study 15354759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonic mechanical ventilation associated with sulphureous water aerosol inhalation
Number of subjects: 2
Study 15354759 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pulmonary ventilation associated with sulphureous water aerosol inhalation medicated with flunisolide
Number of subjects: 2
Study 11006200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg every 3 h up to five doses
Number of subjects: 142
Study 11006200 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg every 3 h up to five doses
Number of subjects: 142
Study 9060013 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine or phenylephrine (30 micrograms in 3 ml)
Number of subjects: 15
Study 9060013 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 8351236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase infusion
Number of subjects: 927
Study 8351236 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 927
Study 8351236 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 927
Study 3034038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10
Study 3034038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg and 10 mg
Number of subjects: 10
Study 3034038 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 2.5 mg
Number of subjects: 10
Study 3034038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28402702 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope system
Number of subjects: 69
Study 28402702 — intervention group
Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 69
Study 26040438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 26040438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24777427 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation colon capsule endoscopy (CCE-2)
Number of subjects: 29
Study 24777427 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 29
Study 23172333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic implants (Group I)
Number of subjects: 109
Study 23172333 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable implants (Group II)
Number of subjects: 109
Study 20124886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership instruction group
Number of subjects: 237
Study 20124886 — intervention group
Group type: COMPARATOR
Intervention: Technical instruction group
Number of subjects: 237
Study 18575629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (5 intramuscular injections at monthly intervals)
Number of subjects: 341
Study 18575629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 18575629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (high antibody levels)
Number of subjects: 341
Study 18575629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (high antibody response)
Number of subjects: 341
Study 15754122 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine (Paxil)
Number of subjects: 94
Study 15754122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 11251132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia (HEA)
Number of subjects: 30
Study 11251132 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with the use of a tourniquet (SPI)
Number of subjects: 30
Study 9058615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir (Vistide, HPMPC) administered every 2 weeks for maintenance treatment with concomitant oral probenecid and intravenous hydration.
Number of subjects: 0
Study 7956593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried meal
Number of subjects: 8
Study 7956593 — intervention group
Group type: COMPARATOR
Intervention: Not fried meal
Number of subjects: 8
Study 3500032 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (15 mg/kg body-weight) with intra-operative autotransfusion (Cell-Saver) in group I
Number of subjects: 200
Study 3500032 — intervention group
Group type: COMPARATOR
Intervention: No autotransfusion in group II
Number of subjects: 200
Study 31937856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 121
Study 30237264 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib and dexamethasone
Number of subjects: 0
Study 30237264 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0
Study 27723226 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0
Study 27723226 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 0
Study 22846446 — intervention group
Group type: EXPERIMENTAL
Intervention: Obituary specifying suicide as the cause of death
Number of subjects: 253
Study 22846446 — intervention group
Group type: COMPARATOR
Intervention: Obituary specifying cancer as the cause of death
Number of subjects: 253